I
Ira Pastan
Researcher at Laboratory of Molecular Biology
Publications - 1304
Citations - 113191
Ira Pastan is an academic researcher from Laboratory of Molecular Biology. The author has contributed to research in topics: Immunotoxin & Pseudomonas exotoxin. The author has an hindex of 160, co-authored 1286 publications receiving 110069 citations. Previous affiliations of Ira Pastan include Heidelberg University & National Institutes of Health.
Papers
More filters
Journal ArticleDOI
The Effect of Dibutyryl Cyclic Adenosine Monophosphate on Synthesis of Sulfated Acid Mucopolysaccharides by Transformed Fibroblasts
TL;DR: Comparison of the rate of sulfate incorporation into acid mucopolysaccharides from the cells indicated that the effect was due to a greater rate of synthesis of these compounds at the time of labeling rather than due to to a decrease in the rates of their degradation.
Journal ArticleDOI
Mobility and distribution of a cell surface glycoprotein and its interaction with other membrane components.
J Schlessinger,Larry S. Barak,Gordon G. Hammes,Kenneth M. Yamada,Ira Pastan,Watt W. Webb,Elliot L. Elson +6 more
TL;DR: Fluorescence photobleaching recovery and immunofluorescence methods have been used to study the lateral mobility and topographical distribution of a major cell surface glycoprotein (CSP) and suggest that CSP molecules do not interact strongly with other CSP molecule under these conditions.
Journal Article
Localization of the forskolin labeling sites to both halves of P-glycoprotein: similarity of the sites labeled by forskolin and prazosin.
D I Morris,L M Greenberger,E P Bruggemann,Carol O. Cardarelli,Michael M. Gottesman,Ira Pastan,K B Seamon +6 more
TL;DR: An iodinated derivative of forskolin, 6-O-[[2-[3-(4-azido-3-[125I] iodophenyl)propionamido]ethyl]carbamyl]forskolin ([ 125I]6-AIPP-Fsk], photolabels the multidrug efflux pump P-glycoprotein in membranes prepared from theMultidrug-resistant cell lines KB-V1 and KB-C1.
Journal ArticleDOI
Removal of B cell epitopes as a practical approach for reducing the immunogenicity of foreign protein-based therapeutics.
Satoshi Nagata,Ira Pastan +1 more
TL;DR: Experimental data summarized in this review indicates that removal of B cell epitopes is a practical approach for making less immunogenic protein therapeutics from non-human functional proteins.
Journal ArticleDOI
Recombinant immunotoxins for treating cancer
TL;DR: The initial evaluation of BL22 is reported on, a recombinant immunotoxin targeted to CD22 expressed on the surface of B-cell malignancies that is evaluated for anticancer activity in humans.